ANI Pharmaceuticals (NASDAQ:ANIP) Issues FY 2025 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share guidance of 6.270-6.620 for the period, compared to the consensus earnings per share estimate of 6.340. The company issued revenue guidance of $768.0 million-$793.0 million, compared to the consensus revenue estimate of $769.6 million.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a “buy” rating and a $80.00 price objective on the stock. StockNews.com downgraded ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 24th. JPMorgan Chase & Co. initiated coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price objective for the company. Guggenheim reaffirmed a “buy” rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. Finally, Truist Financial lifted their target price on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a “hold” rating in a research report on Monday, April 21st. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $80.13.

ANI Pharmaceuticals Trading Up 1.0 %

ANIP opened at $71.53 on Friday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock’s fifty day moving average is $66.71 and its two-hundred day moving average is $60.64. The company has a market capitalization of $1.56 billion, a P/E ratio of -130.05 and a beta of 0.56. ANI Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $83.97.

Insider Activity

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $60.20, for a total value of $60,200.00. Following the completion of the transaction, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at approximately $4,131,164.80. The trade was a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,200 shares of company stock worth $197,792. Company insiders own 12.70% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.